Annals of Hematology

, Volume 98, Issue 5, pp 1319–1321 | Cite as

Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis

  • Yan Li
  • Haigang Shao
  • Bin FuEmail author
Letter to the Editor

Dear Editor,

Additional chromosomal abnormalities (ACAs) occurs in < 10% of patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) [1, 2]. The most common ACAs are unbalanced chromosomal abnormalities, including +Ph, +8, i(17)(q10), and +19 [1, 3]. These changes are considered “major route” ACAs, whereas other infrequent aberrations are designated as “minor route” ACAs [1]. Several recurrent chromosomal rearrangements typically occurring in de novo acute myeloid leukemia (AML), such as t(8;21)(q22,q22), t(15;17)(q22;q21), and inv(16)(p13q22), have been infrequently observed as ACAs of CML (mainly the blast phase [CML-BP]) [4, 5, 6, 7, 8]. We here present a case diagnosed with CML-CP whose leukemia clone harboring both t(9;22)/BCR-ABL1 and t(5;17)/NPM1-RARA.

A 52-year-old man presented with a 2-month history of upper limb numbness. Mild splenomegaly was observed on physical examination. Laboratory tests showed leukocytosis (white blood cells, 66.27 × 10 9/L),...


Funding information

This work was supported by grants from the Hunan Provincial Science and Technology Department (CN) (2010TD2022).

Compliance with ethical standards

Informed consent

Informed consent was obtained from the patient described.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84–90CrossRefGoogle Scholar
  2. 2.
    Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, Testoni N, on behalf of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Working Party on CML (2012) Additional chromosomal abnormalities in Philadelphia-positive clone adverse prognostic influence on frontline imatinib therapy a GIMEMA Working Party on CML analysis. Blood 120:761–767CrossRefGoogle Scholar
  3. 3.
    Chen Z, Shao C, Wang W, Zuo Z, Mou X, Hu SJ, DiGiuseppe JA, Zu Y, Medeiros LJ, Hu S (2017) Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 31:585–592CrossRefGoogle Scholar
  4. 4.
    Salem A, Loghavi S, Tang G, Huh YO, Jabbour EJ, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury JD (2017) Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: a series of 10 cases of a clinically aggressive neoplasm. Am J Hematol 92:520–528CrossRefGoogle Scholar
  5. 5.
    Cai B, Yang W, Zhao Y, Yuan L, Wang L, Gao L, Wang N, Yu L, Gao C (2012) Successful management with an effective induction regimen followed by allogeneic hematopoietic stem cell transplantation for promyelocytic blast crisis of chronic myelogenous leukemia. Ann Hematol 91:621–623CrossRefGoogle Scholar
  6. 6.
    Chung HJ, Chi HS, Cho YU, Park CJ, Seo EJ, Kim KH, Lee JH (2008) Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment. Ann Clin Lab Sci 38:283–286Google Scholar
  7. 7.
    Gozzetti A, Bocchia M, Calabrese S, Pirrotta MT, Crupi R, Raspadori D, Lauria F (2007) Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment. Acta Haematol 117:236–237CrossRefGoogle Scholar
  8. 8.
    Hsiao HH, Tsai HJ, Liu YC, Lee CP, Lin SF (2010) Allo-SCT in a rare t(8;21) evolution of CML. Bone Marrow Transplant 45:1365–1366CrossRefGoogle Scholar
  9. 9.
    De Braekeleer E, Douet-Guilbert N, De Braekeleer M (2014) RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol 7:347–357CrossRefGoogle Scholar
  10. 10.
    O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, Magenis E, Capdeville R, Druker BJ (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628–1633CrossRefGoogle Scholar
  11. 11.
    Cortes JE, Talpaz M, Giles F, O’Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM (2003) Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101:3794–3800CrossRefGoogle Scholar
  12. 12.
    Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S (2016) Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 127:2742–2750CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of HematologyXiangya Hospital Central South UniversityChangshaPeople’s Republic of China
  2. 2.Department of HematologyThe Third Xiangya Hospital of the Central South UniversityChangshaPeople’s Republic of China

Personalised recommendations